• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 - 2025
• Five Forces Analysis
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Application
o Market segments
o Comparison by Application
o Oncology and hematology - Market size and forecast 2020-2025
o Immunology - Market size and forecast 2020-2025
o Endocrinology - Market size and forecast 2020-2025
o Nephrology - Market size and forecast 2020-2025
o Market opportunity by Application
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o Europe - Market size and forecast 2020-2025
o Asia - Market size and forecast 2020-2025
o North America - Market size and forecast 2020-2025
o ROW - Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Amgen Inc.
o Biogen Inc.
o Boehringer Ingelheim International GmbH
o Eli Lilly and Co.
o F. Hoffmann-La Roche Ltd.
o Fresenius Kabi AG
o Merck and Co. Inc.
o Novartis AG
o Pfizer Inc.
o Viatris Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global - Market size and forecast 2020 - 2025 ($ billion)
• 13: Global market: Year-over-year growth 2020 - 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition - Five forces 2020
• 21: Application - Market share 2020-2025 (%)
• 22: Comparison by Application
• 23: Oncology and hematology - Market size and forecast 2020-2025 ($ billion)
• 24: Oncology and hematology - Year-over-year growth 2020-2025 (%)
• 25: Immunology - Market size and forecast 2020-2025 ($ billion)
• 26: Immunology - Year-over-year growth 2020-2025 (%)
• 27: Endocrinology - Market size and forecast 2020-2025 ($ billion)
• 28: Endocrinology - Year-over-year growth 2020-2025 (%)
• 29: Nephrology - Market size and forecast 2020-2025 ($ billion)
• 30: Nephrology - Year-over-year growth 2020-2025 (%)
• 31: Market opportunity by Application
• 32: Customer landscape
• 33: Market share by geography 2020-2025 (%)
• 34: Geographic comparison
• 35: Europe - Market size and forecast 2020-2025 ($ billion)
• 36: Europe - Year-over-year growth 2020-2025 (%)
• 37: Asia - Market size and forecast 2020-2025 ($ billion)
• 38: Asia - Year-over-year growth 2020-2025 (%)
• 39: North America - Market size and forecast 2020-2025 ($ billion)
• 40: North America - Year-over-year growth 2020-2025 (%)
• 41: ROW - Market size and forecast 2020-2025 ($ billion)
• 42: ROW - Year-over-year growth 2020-2025 (%)
• 43: Key leading countries
• 44: Market opportunity by geography ($ billion)
• 45: Impact of drivers and challenges
• 46: Vendor landscape
• 47: Landscape disruption
• 48: Industry risks
• 49: Vendors covered
• 50: Market positioning of vendors
• 51: Amgen Inc. - Overview
• 52: Amgen Inc. - Business segments
• 53: Amgen Inc. - Key offerings
• 54: Amgen Inc. - Key customers
• 55: Amgen Inc. - Segment focus
• 56: Biogen Inc. - Overview
• 57: Biogen Inc. - Business segments
• 58: Biogen Inc. - Key offerings
• 59: Biogen Inc. - Key customers
• 60: Biogen Inc. - Segment focus
• 61: Boehringer Ingelheim International GmbH - Overview
• 62: Boehringer Ingelheim International GmbH - Business segments
• 63: Boehringer Ingelheim International GmbH - Key offerings
• 64: Boehringer Ingelheim International GmbH - Key customers
• 65: Boehringer Ingelheim International GmbH - Segment focus
• 66: Eli Lilly and Co. - Overview
• 67: Eli Lilly and Co. - Business segments
• 68: Eli Lilly and Co. - Key offerings
• 69: Eli Lilly and Co. - Key customers
• 70: Eli Lilly and Co. - Segment focus
• 71: F. Hoffmann-La Roche Ltd. - Overview
• 72: F. Hoffmann-La Roche Ltd. - Business segments
• 73: F. Hoffmann-La Roche Ltd. - Key offerings
• 74: F. Hoffmann-La Roche Ltd. - Key customers
• 75: F. Hoffmann-La Roche Ltd. - Segment focus
• 76: Fresenius Kabi AG - Overview
• 77: Fresenius Kabi AG - Business segments
• 78: Fresenius Kabi AG - Key offerings
• 79: Fresenius Kabi AG - Key customers
• 80: Fresenius Kabi AG - Segment focus
• 81: Merck and Co. Inc. - Overview
• 82: Merck and Co. Inc. - Business segments
• 83: Merck and Co. Inc. - Key offerings
• 84: Merck and Co. Inc. - Key customers
• 85: Merck and Co. Inc. - Segment focus
• 86: Novartis AG - Overview
• 87: Novartis AG - Business segments
• 88: Novartis AG - Key offerings
• 89: Novartis AG - Key customers
• 90: Novartis AG - Segment focus
• 91: Pfizer Inc. - Overview
• 92: Pfizer Inc. - Business segments
• 93: Pfizer Inc. - Key offerings
• 94: Pfizer Inc. - Key customers
• 95: Pfizer Inc. - Segment focus
• 96: Viatris Inc. - Overview
• 97: Viatris Inc. - Business segments
• 98: Viatris Inc. - Key offerings
• 99: Viatris Inc. - Key customers
• 100: Viatris Inc. - Segment focus
• 101: Currency conversion rates for US$
• 102: Research Methodology
• 103: Validation techniques employed for market sizing
• 104: Information sources
• 105: List of abbreviations

Companies Mentioned
. Amgen Inc.
. Biogen Inc.
. Boehringer Ingelheim International GmbH
. Eli Lilly and Co.
. F. Hoffmann-La Roche Ltd.
. Fresenius Kabi AG
. Merck and Co. Inc.
. Novartis AG
. Pfizer Inc.
. Viatris Inc.